CELLECTIVE THERAPEUTICS

cellective-therapeutics-logo

Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

#SimilarOrganizations #People #Financial #More

CELLECTIVE THERAPEUTICS

Industry:
Biotechnology Health Care Therapeutics

Founded:
2003-01-01

Address:
Gaithersburg, Maryland, United States

Country:
United States

Status:
Active

Total Funding:
27.5 M USD


Similar Organizations

anthos-therapeutics-logo

Anthos Therapeutics

Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases.

cisthera-logo

CisThera

CisThera is a private biopharmaceutical company that is developing novel therapeutics for cancer and autoimmune diseases.

not_available_image

Keyhole Therapeutics

Keyhole Therapeutics is a discovery stage drug company specializing in immunotherapies for cancer and autoimmune diseases.

Current Employees Featured

dr-thomas-f-tedder_image

Dr. Thomas F. Tedder
Dr. Thomas F. Tedder Founder @ Cellective Therapeutics
Founder

Founder


dr-thomas-f-tedder_image

Dr. Thomas F. Tedder

Investors List

medimmune-ventures_image

MedImmune Ventures

MedImmune Ventures investment in Series A - Cellective Therapeutics

ba-venture-partners-2_image

BA Venture Partners

BA Venture Partners investment in Series A - Cellective Therapeutics

genentech_image

Genentech

Genentech investment in Series A - Cellective Therapeutics

intersouth-partners_image

Intersouth Partners

Intersouth Partners investment in Series A - Cellective Therapeutics

alta-partners_image

Alta Partners

Alta Partners investment in Series A - Cellective Therapeutics

forward-ventures_image

Forward Ventures

Forward Ventures investment in Series A - Cellective Therapeutics

sofinnova-ventures_image

Sofinnova Investments

Sofinnova Investments investment in Series A - Cellective Therapeutics

latterell-venture-partners_image

Latterell Venture Partners

Latterell Venture Partners investment in Series A - Cellective Therapeutics

More informations about "Cellective Therapeutics"

Cellective Therapeutics 2025 Company Profile: Valuation, Investors ...

Information on acquisition, funding, cap tables, investors, and executives for Cellective Therapeutics. Use the PitchBook Platform to explore the full profile.See details»

Cellective Therapeutics - Funding, Financials, Valuation & Investors

Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases.See details»

Cellective Therapeutics - Products, Competitors, Financials, โ€ฆ

About Cellective Therapeutics Cellective was developing several new pharmaceuticals treating B Cell related cancer and immune diseases. The technology is based on research by Founder โ€ฆSee details»

Cellective Therapeutics - Company Profile - Tracxn

Feb 20, 2025 Cellective Therapeutics - Biotech research company working on B Cell Research for cancer and autoimmune diseases, acquired by MedImmune in 2005. Raised a total funding โ€ฆSee details»

Cellective AI

Cellective AI is pioneering next-generation cancer treatment by training immune cells with AI-driven technology. Discover how we are transforming immunotherapy without genetic โ€ฆSee details»

Cellective Therapeutics - intersouth

Cellective Therapeutics Cellective Therapeutics was founded with technology created by Dr. Tom Tedder, a recognized world leader in B-cell biology and Chairman of the Department of โ€ฆSee details»

Cellective Therapeutics Inc - Company Profile and News

Company profile page for Cellective Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»

Cellective Therapeutics - Ownership and Business Overview - Mergr

Cellective Therapeutics was a biopharmaceutical company focused on developing monoclonal antibodies for the treatment of oncology and autoimmune diseases such as B-cell lymphoma, โ€ฆSee details»

Cellective Therapeutics, Inc. | Company | Mindmaps

Cellective Therapeutics was founded with technology created by Dr. Tom Tedder, a recognized world leader in B-cell biology and Chairman of the Department of Immunology at Duke University.See details»

MedImmune Completes Cellective Acquisition - bionity.com

MedImmune, Inc. announced that it has completed its acquisition of Cellective Therapeutics, Inc., a private Maryland-based biopharmaceutical company focused on the development of โ€ฆSee details»

Cellective BioTherapy - Crunchbase Company Profile & Funding

Cellective BioTherapy develops novel cellular and monoclonal antibody-based platforms to treat cancer, autoimmunity, and immunodeficiency.See details»

Thomas F. Tedder - Founder, CEO & Director at Cellective โ€ฆ

He founded Cellective Therapeutics in 2003 with the largest Series A financing in the Southeast at that time. The company was acquired by MedImmune/AstraZeneca in 2005. In 2015, he โ€ฆSee details»

Lisa-Beth Ferstenberg, M.D. | miRecule

She was founding CEO of Cellective Therapeutics, Inc., a venture backed company that developed a monoclonal antibody for autoimmune indications, which was acquired by โ€ฆSee details»

Cellective Therapeutics, Inc - VentureRadar

IntelliWheels, Inc., is a startup company out of the University of Illinois at Urbana-Champaign that develops technology to improve mobility options for wheelchair users. It was founded by Scott โ€ฆSee details»

MedImmune to buy Cellective Therapeutics - Fierce Biotech

Sep 13, 2005 Gaithersburg, Maryland-based MedImmune has signed a deal to buy Cellective Therapeutics in an all-cash transaction. MedImmune didn't say how much it was paying for โ€ฆSee details»

MedImmune Gaining Antibodies Through Cellective Acquisition

Sep 15, 2005 A year after raising $27 million in its Series A round, Cellective Therapeutics Inc. is being acquired by its larger neighbor, MedImmune Inc. The move might be somewhat of a โ€ฆSee details»

Matt Jenkins - QHP Capital

Prior to Allscripts, Mr. Jenkins was one of the three founding members of Cellective Therapeutics (acquired by Medimmune), a biopharmaceutical firm focused on the development of โ€ฆSee details»

Cellective Therapeutics, Inc.: ่ฏ็‰ฉ็ฎก็บฟ๏ผŒไธ“ๅˆฉ๏ผŒไธดๅบŠ่ฏ•้ชŒ - ๆ™บๆ…ง่Šฝ โ€ฆ

ไบ†่งฃCellective Therapeutics, Inc.ๅ…ฌๅธ็š„่ฏ็‰ฉ็ฎก็บฟ๏ผŒๆฒป็–—้ข†ๅŸŸ๏ผŒๆŠ€ๆœฏๅนณๅฐ๏ผŒไปฅๅŠๅฎƒ็š„1็ฏ‡ๆ–ฐ้—ปใ€‚See details»

Cellective Therapeutics-ๅŠจ่„‰็ฝ‘ - vbdata.cn

Cellective Therapeutics, Inc.ไธ€ๅฎถ่ฏ็‰ฉๅผ€ๅ‘ๅ…ฌๅธ๏ผŒ่‡ดๅŠ›ไบŽๅ‘็Žฐใ€ๅผ€ๅ‘ๅ’Œๅ•†ไธšๅŒ–็”จไบŽๆฒป็–—B็ป†่ƒž็™Œๅ’Œ่‡ช่บซๅ…็–ซ็–พ็—…็š„ๅ•ๅ…‹้š†ๆŠ—ไฝ“ใ€‚ ๅ…ถไบงๅ“ๅŒ…ๆ‹ฌ้’ˆๅฏนB็ป†่ƒžๆŠ—ๅŽŸ็š„ๅ•ๅ…‹้š†ๆŠ—ไฝ“CD19๏ผŒCD20ๅ’ŒCD22ๅค„ โ€ฆSee details»

Federal government announces support for cutting-edge, AI- and โ€ฆ

2 days ago OmniaBio Inc. is a technology-focused, global cell and gene therapy contract development and manufacturing organization. A subsidiary of the Centre for โ€ฆSee details»

linkstock.net © 2022. All rights reserved